75 Shoreway Road, Suite D
25 articles with Alkahest, Inc.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
8/26/2019Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
7/26/2019Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments.
Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201.
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease
Alkahest, Inc. announced the dosing of the first subject with severe Alzheimer's disease in a Phase 2 clinical trial of GRF6019 in collaboration with development partner Grifols.
Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress
Alkahest, Inc. will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-naïve patients at the Retina World Congress in Fort Lauderdale, Florida on March 24, 2019 at 11:33 a.m. EST.
Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration
Both treatment naïve and treatment refractory individuals experienced improved visual acuity
Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson's Disease and Cognitive Impairment
Grant funding by The Michael J. Fox Foundation will support Phase 2 trial
11/26/2018In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Alkahest, Inc. today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer.
Presentations highlight a novel multifactorial approach to treating neurodegenerative diseases
Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine's 50 Most Influential People in Health Care
Alkahest Inc. announced today that Tony Wyss-Coray Ph.D., Alkahest's co-founder and board member was named to TIME Health's list of individuals who were most influential in transforming healthcare in 2018.
Alkahest Presentation at Clinical Trials in Alzheimer's Disease (CTAD) Conference October 26, 2018, Barcelona, Spain
Alkahest provided update on their novel multifactorial approach to the treatment of Alzheimer's Disease
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations
Alkahest to Present at Alzheimer's Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL
Presentations highlight a novel multifactorial approach to the treatment of Alzheimer's Disease
Michael Byrnes joins Alkahest as Chief Financial Officer
Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson's Disease
Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) entitled "Development of ALK4290 as a novel PD therapeutic" under the Principal Investigator S. Sakura Minami, Ph.D.